Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing

The investigator will divide the participants into two groups e.g. group (A) and group (B) according to Hemoglobin level and receiving of oral supplementation for IDA accompanied with health education in case of group (A) and without health education in case of group (B). Then the investigator asked patient to sign the document of her investigations result to receive iron supplementation.

• After that, the investigator observes hemoglobin's Level, when it less than >11g/dl, the patient will be the group (A) who will receive oral iron supplementation and health education.
• Group (B) who will receive Total Dose Infusion (TDI) without health education.

Inclusion criteria

• Pregnant Women aged >18 years
• Hemoglobin<10g/dl
• Gestational age between 14-28 weeks
• Singleton pregnancy
• Willingness to participate and signing the informed consent form

Exclusion criteria

• Anemia predominantly caused by factors other than IDA (e.g. anemia with untreated B12 or foliate deficiency, hemolytic anemia),
• Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and haemosidrosis).
• Decompensated liver cirrhosis and active hepatitis (ALAT>3 times upper limit of normal).
• Active acute or chronic infections (assessed by clinical judgment supplied with white Blood Cells (WBC) and C - reactive protein (CRP).
• Rheumatoid arthritis with symptoms or signs of active inflammation.
• Multiple allergies.
• Known hypersensitivity to parental iron or any recipients in the investigational drug products.
• Erythropoietin treatment within 8 weeks prior to the screening visit.
• Other iron treatment within 8 weeks prior to the screening visit.
• Planned elective surgery during the study.
• Participation in any other clinical within 3 months prior to the screening.
• Any other medical condition e.g. malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus.